Detection of a negative correlation between prescription of Chinese herbal products containing coumestrol, genistein or daidzein and risk of subsequent endometrial cancer among tamoxifen-treated female breast cancer survivors in Taiwan between 1998 and 2008: A population-based study

Journal of Ethnopharmacology

Volumn 169, Issue , 2015, Pages 356-362

  Hu, Yi Cheng ^a,b   Wu, Chien Tung ^a   Lai, Jung Nien ^a,c,d   Tsai, Yueh Ting ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d Taiwan Association for Traditional Chinese Medicine of Family   (Taiwan)

Author keywords

Breast cancer; Chinese herbal product; Coumestrol; Daidzein; Genistein; Herb drug interaction; National health insurance research database; Phytoestrogen; Tamoxifen

Indexed keywords

COUMESTROL; DAIDZEIN; GENISTEIN; HERBACEOUS AGENT; TAMOXIFEN; ISOFLAVONE DERIVATIVE;

ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SURVIVOR; CHINESE HERB; ENDOMETRIUM CANCER; FEMALE; HUMAN; MIDDLE AGED; NONHUMAN; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; TAIWAN; YOUNG ADULT; BREAST NEOPLASMS; CASE CONTROL STUDY; CHEMICALLY INDUCED; ENDOMETRIAL NEOPLASMS; STATISTICS AND NUMERICAL DATA; SURVIVOR;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COUMESTROL; DRUGS, CHINESE HERBAL; ENDOMETRIAL NEOPLASMS; FEMALE; GENISTEIN; HUMANS; ISOFLAVONES; MIDDLE AGED; SURVIVORS; TAIWAN; TAMOXIFEN; YOUNG ADULT;

EID: 84929393278     PISSN: 03788741     EISSN: 18727573     Source Type: Journal    
DOI: 10.1016/j.jep.2015.04.028     Document Type: Article

References (35)

1. M. Andersson Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer J. Natl. Cancer. Inst. 83 14 1991 1013 1017
2. H. Adlercreutz Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet Am. J. Clin. Nutr. 54 1991 1093 1100
3. C.H. Adlercreutz Soybean phytoestrogen intake and cancer risk J. Nutr. 125 Suppl. 3 1995 757S 770S
4. L. Bernstein Tamoxifen therapy for breast cancer and endometrial cancer risk J. Natl. Cancer Inst. 91 19 1999 1654 1662
5. L. Bergman Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen Lancet 356 9233 2000 881 887
6. M.E. Baker Endocrine activity of plant-derived compounds: an evolutionary perspective Proc. Soc. Exp. Biol. Med. 208 1995 131 138
7. J. Cuzick Overview of the main outcomes in breast-cancer prevention trials Lancet 361 9354 2003 296 300
8. Chien-Tung Wu Prescription profile of Chinese herbal productscontaining coumestrol, genestein, and/or daidzein among female users: an analysis of national health insurance data in Taiwan between1997 and 2007 Chin. Med. 7 2012 1 6
9. M.C. Chen Concurrent use of conventional drugs with Chinese herbal products in taiwan: a population-based study J. Tradit. Complement. Med. 3 2013 256 262
10. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 9114 1998 1451 1467
11. T. Fornander Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers Lancet 1 8630 1989 117 120
12. B. Fisher Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J. Natl. Cancer. Inst. 86 7 1994 527 537
13. K. Gelmon One step forward or one step back with tamoxifen? Lancet 356 9233 2000 868 869
14. L. Hardell Pelvic irradiation and tamoxifen as risk factors for carcinoma of corpus uteri Lancet 2 8625 1988 1432
15. S.C. Hsieh The prescribing of Chinese herbal products in Taiwan: a cross-sectional analysis of the national health insurance reimbursement database Pharmacoepidemiol. Drug Saf. 17 6 2008 609 619
16. G. Josephine Expression of estrogen receptor alpha and beta during mouse embryogenesis Mech. Dev. 81 1999 163 167
17. Gaete Leonardo Daidzein-estrogen interaction in the rat uterus and its effect on human breast cancer cell growth J. Med. Food 15 12 2012 1081 1090
18. J.N. Lai Observational studies on evaluating the safety and adverse effects of traditional Chinese medicine Evid.-Based Complement. Altern. Med. 2013 2013 697893
19. K.H. Lee Concurrent use of hypnotic drugs and Chinese herbal medicine therapies among taiwanese adults with insomnia symptoms: a population-based study Evid.-Based Complement. Altern. Med. 2013 2013 987862
20. J.N. Lai Prescription pattern of Chinese herbal products for breast cancer in Taiwan: a population-based study Evid.-Based Complement. Altern. Med. 2012 2012 891893
21. Y.J. Lin Puerariae radix isoflavones and their metabolites inhibit growth and induce apoptosis in breast cancer cells Biochem. Biophys. Res. Commun. 378 2009 683 688
22. Y. Li Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer Mol. Cancer 12 2013 9
23. H. Mignotte Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) Int. J. Cancer 76 3 1998 325 330
24. M.J. Messina Soy intake and cancer risk:a review of the in vitro and in vivo data Nutr. Cancer 21 1994 113 131
25. R.J. Miksicek Estrogenic flavonoids: structural requirements for biological activity Proc. Soc. Exp. Biol. Med. 208 1995 44 50
26. A. Molteni In vitro hormonal effects of soybean isoflavones J. Nutr. 125 1995 751S 756S
27. Ming Zhu Fang Reversal of hypermethylation and reactivation of p16INK4a, RARb, and MGMT genes by genistein and other isoflavones from soy Clin. Cancer Res. 11 2005 7033 7041
28. D.P. Rose Dietary fiber, phytoestrogens, and breast cancer Nutrition 8 1992 47 51
29. A.J. Swerdlow Tamoxifen second cancer study G. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study J. Natl. Cancer. Inst. 97 5 2005 375 384
30. A.J. Sasco Tamoxifen and menopausal status: risks and benefits Lancet 347 9003 1996 761
31. D.M. Sheehan The case for expanded phytoestrogen research Proc. Soc. Exp. Biol. Med. 208 1995 3 5
32. K.D. Setchell Mammalian lignans and phytoestrogens recent studies on their formation, metabolism and biological role in health and disease I. Rowland, Role of the Gut Flora in Toxicity and Cancer 1998 Academic Press Limited London (U.K.) 315 345
33. F.E. Van Leeuwen Risk of endometrial cancer after tamoxifen treatment of breast cancer Lancet 343 8895 1994 448 452
34. Vittorio Unfer Endometrial effects of long-term treatment with phytoestrogens: a randomized double-blind, placebo-controlled study Fertil. Steril. 7 1 2004 145 148
35. Z. Yu Induction of apoptosis by puerarin in colon cancer HT-29cells Cancer Lett. 238 2006 53 60